| Bioactivity | OXSI-2 is a bioavailable, cell-permeable Syk inhibitor with an EC50 of 313 nM and an IC50 of 14 nM[1][2]. |
| Invitro | OXSI-2 (2 μM) completely inhibits Convulxin-induced platelet aggregation and shape change. OXSI-2 (2 μM) also completely blocks GPVI-mediated dense granule release. OXSI-2 (100 nM) does not affect the platelet functional responses induced by Convulxin, and modest shape change is still evident at 1 μM[1].Adaptor protein LAT is a known substrate of Syk Kinase. OXSI-2 completely inhibits LAT Y191 phosphorylation. OXSI-2 inhibits Syk mediated events in platelets[1].OXSI-2 (2 μM) inhibits inflammasome assembly, caspase-1 activation, IL-1β processing and release, mitochondrial ROS generation, and pyroptotic cell death[2]. Western Blot Analysis[1] Cell Line: |
| Name | OXSI-2 |
| CAS | 622387-85-3 |
| Formula | C18H15N3O3S |
| Molar Mass | 353.40 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Kamala Bhavaraju, et al. Evaluation of [3-(1-methyl-1H-indol-3-yl-methylene)-2-oxo-2, 3-dihydro-1H-indole-5-sulfonamide] (OXSI-2), as a Syk-selective inhibitor in platelets. Eur J Pharmacol. 2008 Feb 12;580(3):285-90. [2]. Jordan R Yaron, et al. The oxindole Syk inhibitor OXSI-2 blocks nigericin-induced inflammasome signaling and pyroptosis independent of potassium efflux. Biochem Biophys Res Commun. 2016 Apr 8;472(3):545-50. |